|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000035097 |
|
最近更新日期: Date of Last Refreshed on: |
2020-07-31 18:39:58 |
|
注册时间: Date of Registration: |
2020-07-31 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
审核中 评价止血带对膝关节置换术患者股四头肌形态与功能影响的前瞻性随机对照研究 |
|
Public title: |
the effect of tourniquet application on the morphology and function of quadriceps in patients undergoing total knee arthroplasty: a prospective randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
评价止血带对膝关节置换术患者股四头肌形态与功能影响的前瞻性随机对照研究 |
|
Scientific title: |
the effect of tourniquet application on the morphology and function of quadriceps in patients undergoing total knee arthroplasty: a prospective randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王鑫光 |
研究负责人: |
李杨 |
|
Applicant: |
Xinguang Wang |
Study leader: |
Yang Li |
|
申请注册联系人电话: Applicant telephone: |
+86-18211070116 |
研究负责人电话: Study leader's telephone: |
+86-13810634362 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wangxinguang@bjmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
liyangdr@bjmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区花园北路49号 |
研究负责人通讯地址: |
北京市海淀区花园北路39号 |
|
Applicant address: |
No. 49 North Garden Road,Haidian Disrict, Beijing, China |
Study leader's address: |
No. 49 North Garden Road,Haidian Disrict, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
100191 |
研究负责人邮政编码: Study leader's postcode: |
100191 |
|
申请人所在单位: |
北京大学第三医院 |
||
|
Applicant's institution: |
Peking University Third Hospital |
||
|
研究负责人所在单位: |
北京大学第三医院 |
||
|
Affiliation of the Leader: |
Peking University Third Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
M2020290 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京大学第三医院医学科学研究伦理委员会 |
||
|
Name of the ethic committee: |
Peking University Third Hospital Medical Science Research Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-07-15 00:00:00 |
||
|
伦理委员会联系人: |
宋纯理 |
||
|
Contact Name of the ethic committee: |
Chunli Song |
||
|
伦理委员会联系地址: |
北京市海淀区花园北路49号 |
||
|
Contact Address of the ethic committee: |
No. 49 North Garden Road,Haidian Disrict, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
010-82266872 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京大学第三医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Peking University Third Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区花园北路49号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 49 North Garden Road,Haidian Disrict, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京大学第三医院院临床重点项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Key Clinical Projects of Peking University Third Hospital |
||||||||||||||||||||||
|
Target disease: |
knee osteoarthritis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
评价止血带对膝关节置换术患者股四头肌形态与功能影响的前瞻性随机对照研究 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the effect of tourniquet application on the morphology and function of quadriceps in patients undergoing total knee arthroplasty |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)经症状、查体以及影像学检查,诊断为原发性膝关节骨性关节炎,X线K-L分期III期及以上; |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Primary knee osteoarthritis was diagnosed by symptoms, physical examination and imaging examination, with X-ray K-L stage III or above; |
||||||||||||||||||||||
|
排除标准: |
(1)既往因心脑血管疾病需长期服用抗凝药物3个月以上且未停药(阿司匹林/氯吡格雷<7天,华法林<5天或利血平<7天),或合并下列疾患:肾功能不全(血尿素氮≥25.3mmol/L或血肌酐≥442umol/L)、肝功能不全(ALT或AST≥80U/L)、严重心脏疾患(或近12个月行冠脉支架植入术)、严重呼吸系统疾患(肺功能FEV1.0<0.5L或FEV1.0/FVC<60%)、VTE病史或血栓形成高风险(遗传性/获得性血栓性疾病)、凝血功能障碍(APTT≥46秒或INR≥1.7)、中风以及恶性肿瘤病史; |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Previous long-term use of anticoagulant drugs for cardiovascular and cerebrovascular diseases for more than 3 months without stopping (aspirin/clopidogrel <7 days, warfarin <5 days or reserpine <7 days), or combined the following diseases: renal insufficiency (blood urea nitrogen ≥25.3mmol/L or blood creatinine ≥442umol/L), liver insufficiency (ALT or AST≥80U/L), severe heart disease (or coronary stent implantation in the last 12 months), severe respiratory diseases (pulmonary function FEV1.0<0.5L or FEV1.0/FVC<60%), history of VTE or high risk of thrombosis (hereditary/acquired thrombotic diseases), coagulation dysfunction (APTT≥46 seconds or INR≥1.7)or history of stroke and malignant tumor. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-07-15 00:00:00至 To 2023-07-15 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-08-03 00:00:00 至 To 2021-08-03 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
用SAS 9.4软件产生区组随机序列,打印入随机信封。在研究开展时,研究对象知情同意后,由研究者依次拆开随机信封,按照对应的数字组号,决定研究对象的分组情况。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
SAS 9.4 software was used to generate the random sequence, and then printed into the random envelope. After the informed consent signed,the researchers opened the random envelope, and determined the grouping according to the corresponding group number. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2024年公开,采用第三方网络平台公布 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
All data will be shared in 2024 on a third party netework platform |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
使用病例记录表进行收据采集,采用微软Excel程序进行收据管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Use the case record form for data collection and EXCEL for data management |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |